ALNYLAM PHARMACEUTICALS, INC. - COM (ALNY)

Historical Portfolio Holders from Q1 2014 to Q3 2024

All holders as of June 30, 2024
Q2 2024
Type / Class
Equity / COM
Shares, excl. options Q2 2024
120M
Holdings value Q2 2024
$29.1B
Value change Q2 2024
+$1.98B
Grand Portfolio weight change Q2 2024
+0.004%
Number of holders
509
Number of buys Q2 2024
268
Number of sells Q2 2024
-215
Average buys Q2 2024 %
+0.004%
Average sells Q2 2024 %
-0.006%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 83.5K $23M +$1.08M $275.03 8
2024 Q2 120M $29.1B +$1.98B $243.00 516
2024 Q1 112M $16.8B -$860M $149.45 492
2023 Q4 117M $22.4B +$118M $191.41 488
2023 Q3 116M $20.6B -$344M $177.10 446
2023 Q2 118M $22.4B -$212M $189.94 461
2023 Q1 119M $23.9B +$26.4M $200.32 462
2022 Q4 119M $28.3B -$3.11B $237.65 476
2022 Q3 133M $26.6B +$3.4B $200.16 476
2022 Q2 113M $16.5B -$67.6M $145.85 410
2022 Q1 113M $18.5B +$320M $163.29 420
2021 Q4 112M $18.9B +$64.2M $169.58 420
2021 Q3 111M $21B -$163M $188.81 392
2021 Q2 112M $19B +$501M $169.52 392
2021 Q1 109M $15.4B +$206M $141.19 380
2020 Q4 108M $14B -$112M $129.97 352
2020 Q3 108M $15.8B -$457M $145.60 350
2020 Q2 111M $16.5B +$490M $148.11 365
2020 Q1 108M $11.8B +$295M $108.85 320
2019 Q4 105M $12.1B -$234M $115.17 307
2019 Q3 108M $8.68B +$175M $80.42 277
2019 Q2 106M $7.69B +$801M $72.56 283
2019 Q1 96.7M $9.03B +$427M $93.45 283
2018 Q4 92.3M $6.73B +$108M $72.91 272
2018 Q3 90.6M $7.93B -$106M $87.52 299
2018 Q2 91.5M $9.01B -$37M $98.49 306
2018 Q1 91.6M $10.9B -$75.9M $119.10 291
2017 Q4 92.1M $11.7B +$613M $127.05 277
2017 Q3 87.4M $10.3B +$85.9M $117.49 228
2017 Q2 87M $6.93B +$485M $79.76 217
2017 Q1 82.3M $4.22B +$358M $51.25 190
2016 Q4 79.5M $2.98B -$14.9M $37.44 199
2016 Q3 77.5M $5.25B +$229M $67.78 253
2016 Q2 74.1M $4.11B +$154M $55.49 239
2016 Q1 70.9M $4.45B +$295M $62.77 247
2015 Q4 66M $6.21B +$83.2M $94.14 256
2015 Q3 63.5M $5.1B -$64.8M $80.36 254
2015 Q2 63.8M $7.64B +$133M $119.87 273
2015 Q1 64.5M $6.73B +$671M $104.42 235
2014 Q4 58M $5.62B -$127M $97.00 213
2014 Q3 59M $4.61B +$102M $78.10 185
2014 Q2 57.8M $3.65B +$120M $63.17 194
2014 Q1 55.7M $3.74B +$8.75M $67.14 194